# Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV

> **NCT00863239** · PHASE2 · COMPLETED · sponsor: **Biolex Therapeutics, Inc.** · enrollment: 116 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** ribavirin
- **DRUG:** Locteron™ (controlled-release interferon alpha 2b)
- **DRUG:** PEG-Intron™

## Key facts

- **NCT ID:** NCT00863239
- **Lead sponsor:** Biolex Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2010-11
- **Final completion:** 2011-11
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2012-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00863239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00863239, "Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT00863239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*